Vol.

No.

July 11, 2025Jul 11, 2025

DOWNLOAD THE PDF

First-ever financial toxicity tumor board aims to change the standard of care Researchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI

Cover Story

Clinical

First-ever financial toxicity tumor board aims to change the standard of care

Researchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI

By Claire Marie Porter

Nearly half of cancer patients and survivors in the United States face medical debt so crushing that it has sparked a relatively new focus within oncology: financial toxicity.

Conversation with The Cancer Letter

HHS seems poised to exert control over USPSTF
Ransohoff: The task force is the pinnacle of evidence-based medicine

By Paul Goldberg

Guest Editorial

Understanding the impact of the Israeli-U.S. attacks on Iran’s nuclear facilities

By Robert Peter Gale

Clinical Trials & Tribulations

An overlooked immune cell population may offer new direction for cell and gene therapy

By Arthur Machlenkin

Unraveling connections between diabetes and cancer: Insights from metabolism research at City of Hope

By Charles Brenner

Free In the Archives

Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology

By Katie Goldberg

Cancer Policy

Supreme Court lifts lower-court freeze on RIFs

House Dems host “The Things We’ll Never Know: A Science Fair of Canceled Grants”

In the name of “radical transparency,” FDA touts publication of 200 complete response letters

HHS asks employees to report instances of “DEI policies that caused discrimination”

Medical, cancer groups respond to Trump’s “Big Beautiful Bill” becoming law

In Brief

Mary Beckerle to step down as CEO at Huntsman, succeeded by Brad Cairns

Kim Rhoads named associate director of community outreach and engagement VCU Massey

John Leonard named director of Center for Blood Cancers, chief of Division of Hematology and Medical Oncology at NYU Langone

Michael Byrne named medical director for cellular therapy at OneOncology

Arjan Gower receives NCCN grant to study a targeted therapy for early-stage NSCLC with rare EGFR mutations

Robert A. Winn Clinical Investigator Pathway Program launches fourth cohort of medical students

American Society for Radiation Oncology announces 2025 fellows

MASCC announces inaugural cohort of fellows

Funding Opportunities

NCI, SITC immunotherapy fellowship calls for applications

Clinical Roundup

Subtle challenges to women’s authority increases burnout among surgeons, survey data shows

Xtandi + leuprolide improves OS in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, phase III data show

Steroids may make immunotherapy less effective for lung cancer patients, retrospective study finds

Neoadjuvant ablative radiotherapy + chemo reduces risk of pancreatic cancer regrowth, stimulates immune system, cohort study finds

Weight-associated breast cancer risk is higher in women with cardiovascular disease, IARC analysis shows

Common autoimmune drug may help reverse immunotherapy-induced diabetes, UCLA preclinical study finds

AI could help pathologists match cancer patients to the right treatments faster and more efficiently, study shows

PARP1 inhibitors halt EBV-driven lymphoma by disrupting a key cancer pathway, preclinical study finds

“Power surges” on cancer cell membranes may fuel progression of disease, Johns Hopkins study finds

UCLA study identifies key protein that helps liver cancer resist heat-based treatment

Cardiac biomarkers linked to future cancer risk, even without heart disease, says UCLA prospective cohort study

Drugs & Targets

Personalis, Tempus AI expand commercial partnership focused on ultra-sensitive cancer recurrence testing

China’s NMPA approves lisaftoclax for CLL or SLL

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 34 - September 18, 2026